Start Your Free Review
Answer 2-3 quick questions to review your potential case.
The Rapid Expansion of Pediatric Indications
Dupixent's pediatric history follows an aggressive commercial strategy. The drug was initially approved in March 2017 for adults with moderate-to-severe atopic dermatitis. Sanofi and Regeneron then pursued sequential age-lowering approvals: adolescents (12-17) in March 2019, children (6-11) in June 2020, and infants and young children (6 months to 5 years) in June 2022. Each expansion opened new patient populations and revenue streams. By 2025, Dupixent had also received pediatric approvals for asthma (ages 6+), eosinophilic esophagitis (ages 1+, weight-based), and was being studied in pediatric chronic rhinosinusitis.
The commercial logic was straightforward: atopic dermatitis affects approximately 13 percent of U.S. children, creating an enormous potential market. Dupixent became the first biologic approved for pediatric atopic dermatitis, giving Sanofi first-mover advantage in a market with limited alternatives. Annual Dupixent revenue exceeded $13 billion globally by 2024, with pediatric prescriptions representing a growing share. The financial incentive to expand pediatric use was immense — and the safety data available at the time of each approval was limited to trial durations of 16 to 52 weeks, far too short to detect rare malignancies.
Developing Immune Systems and IL-4/IL-13 Blockade
Interleukin-4 and interleukin-13 are not merely inflammatory mediators — they play fundamental roles in immune system development. IL-4 drives B-cell class switching to IgE and IgG4, directs Th2 differentiation, and influences thymic T-cell selection. IL-13 modulates tissue remodeling, goblet cell hyperplasia, and mucosal immunity. In children, these cytokines are actively shaping the immune repertoire: the T-cell and B-cell populations that will provide lifelong immune protection are being selected, expanded, and programmed during childhood.
Blocking IL-4 and IL-13 during these critical developmental windows introduces a theoretical risk that the adult CTCL signal does not fully capture. Adult Dupixent patients have mature, established immune repertoires — the IL-4/IL-13 blockade modulates a completed system. Pediatric patients are having their immune development altered in real time. The long-term consequences of this alteration — including whether it creates a predisposition to T-cell lymphoproliferative disorders years or decades later — cannot be known from clinical trials that lasted less than one year. Sanofi's pediatric safety data is a snapshot where a time-lapse is needed.
CTCL in Children: Rare But Not Impossible
Cutaneous T-cell lymphoma is predominantly an adult disease, with median age at diagnosis in the mid-50s. However, pediatric CTCL does occur, accounting for approximately 4 to 5 percent of all CTCL cases. Pediatric mycosis fungoides has been documented in patients as young as 2 years old. The literature describes a subset of pediatric CTCL cases that present with hypopigmented patches — a variant more common in children with darker skin tones — that is frequently misdiagnosed as vitiligo, tinea versicolor, or eczema.
The concern for pediatric Dupixent patients is not that children will develop CTCL at the same rate as adults, but that the combination of immune modulation during development plus lifetime exposure risk creates a unique hazard profile. A child started on Dupixent at age 2 who remains on the drug for 5 years has undergone sustained IL-4/IL-13 blockade during the most critical period of immune maturation. Even if Dupixent is discontinued, the immune repertoire alterations may persist. The absence of pediatric CTCL cases in the current litigation does not mean the risk is absent — it means the latency period has not yet elapsed.
Informed Consent and the Parental Decision
Pediatric drug claims carry a heightened duty-to-warn standard because parents are making treatment decisions on behalf of a minor who cannot consent. A parent who agrees to Dupixent for their child's eczema is weighing the known benefit (reduced itching and skin inflammation) against disclosed risks. If the manufacturer fails to disclose a known or knowable risk — such as the emerging CTCL signal — the parent's consent is legally compromised. This is informed consent doctrine applied to the pharmaceutical warning context: the manufacturer's label is the primary vehicle through which risk information reaches the prescriber and, ultimately, the parent.
Sanofi marketed Dupixent to parents of children with eczema through direct-to-consumer advertising that emphasized the emotional toll of pediatric atopic dermatitis and positioned Dupixent as a path to normalcy. These advertisements featured children playing, sleeping comfortably, and attending school without the burden of visible skin disease. The juxtaposition of this hopeful marketing with the undisclosed cancer risk creates a powerful narrative for plaintiffs: Sanofi sold parents a promise of childhood normalcy while concealing a risk that could take that childhood away entirely.
What Parents Should Do Now
Parents of children currently taking or formerly taking Dupixent should take several concrete steps. First, discuss the emerging CTCL risk with the child's dermatologist or allergist and ask whether continued Dupixent use is justified given the evolving safety profile. Second, request a baseline skin examination with documentation of all current lesions, their morphology, and their distribution — this creates a medical record baseline that will be valuable if lesions change character in the future. Third, if the child develops any new, persistent, or morphologically different skin lesions during Dupixent treatment, insist on a skin biopsy rather than accepting a presumptive eczema diagnosis.
Parents whose children have already been diagnosed with CTCL or any T-cell lymphoproliferative disorder after Dupixent use should consult a pharmaceutical liability attorney immediately. Pediatric cancer cases carry significant damages including lifetime medical monitoring, lost developmental milestones, future earning capacity impairment, and the emotional devastation inflicted on the entire family. The statute of limitations for a minor's claim is typically tolled (paused) until the child reaches the age of majority, but the parents' claims may have separate, shorter deadlines. Legal consultation should not be delayed.
Frequently Asked Questions
Related Pages
CTCL Diagnosis After Dupixent Use
Cutaneous T-cell lymphoma is a rare and aggressive blood cancer that masquerades as eczema, psoriasis, and other benign skin conditions — making it uniquely dangerous for Dupixent patients who already carry dermatitis diagnoses. Misdiagnosis rates exceed 40 percent in early-stage CTCL because the symptoms overlap so precisely with the conditions Dupixent is prescribed to treat. Dermatologists expect itchy, red patches in their Dupixent patients; what they may not expect is that those patches now harbor malignant T-cells. Staging ranges from IA (limited patches) to IVB (visceral organ involvement and blood-borne Sezary cells), and the difference between a Stage IA diagnosis and a Stage IIB diagnosis can mean the difference between a normal life expectancy and a five-year survival rate below 40 percent. The critical diagnostic tool is a skin biopsy with immunohistochemistry, which can reveal hallmark Pautrier microabscesses — clusters of malignant T-cells in the epidermis that do not appear in benign dermatitis. Every Dupixent patient whose skin condition worsens, changes character, or fails to respond to continued treatment should demand a biopsy, not another refill.
Dupixent Eye Problems and Ocular Side Effects
Conjunctivitis is the most common adverse event associated with Dupixent, occurring in approximately 30 percent of atopic dermatitis patients in clinical trials — a rate ten times higher than placebo. But conjunctivitis is just the visible surface of a broader ocular toxicity profile that includes blepharitis, keratitis, dry eye syndrome, limbal stem cell deficiency, and in rare but devastating cases, corneal perforation requiring emergency surgical intervention. These eye problems often develop within the first three months of treatment and can persist even after Dupixent is discontinued. Sanofi and Regeneron have acknowledged conjunctivitis on the Dupixent label but have minimized the severity spectrum, leading patients and prescribers to underestimate the risk of serious, vision-threatening complications. For patients who have suffered permanent vision impairment, corneal scarring, or required corneal transplantation due to Dupixent-related ocular injury, the manufacturer's characterization of these events as manageable side effects is contradicted by their clinical experience.
Dupixent MDL Status and Litigation Update
The Judicial Panel on Multidistrict Litigation (JPML) is considering a petition to consolidate all federal Dupixent CTCL lawsuits into a single MDL for coordinated pretrial proceedings. As of early 2026, over 250 individual lawsuits have been filed across multiple federal districts, with plaintiffs proposing consolidation in the Northern District of Georgia (Atlanta) and defendants advocating for the Southern District of New York. MDL No. 3180 would centralize discovery, expert qualification (Daubert) proceedings, and bellwether trial selection under a single transferee judge. For individual plaintiffs, MDL consolidation means coordinated case management and potential leverage from shared discovery, but it also means potential delays as the court works through lead case selection and common issues. The venue decision — Atlanta versus New York versus other candidates — will shape the litigation's procedural landscape, judicial temperament, jury pool demographics, and ultimately the pressure on Sanofi and Regeneron to negotiate a global settlement.
Dupixent Wrongful Death Claims
When cutaneous T-cell lymphoma caused by Dupixent progresses to advanced stages and the patient dies, surviving family members may pursue wrongful death and survival action claims against Sanofi and Regeneron. Richardson v. Sanofi, filed in October 2025 in the Western District of Tennessee, was one of the first named Dupixent CTCL lawsuits and involved allegations of fatal lymphoma progression. Wrongful death claims compensate the decedent's family for loss of companionship, financial support, and funeral expenses, while survival actions compensate the decedent's estate for the pain, suffering, and medical costs the patient endured before death. These are legally distinct claims with different standing requirements, damage calculations, and statutes of limitations. State law controls who may bring a wrongful death claim — in some states, only a surviving spouse or children have standing, while in others, parents, siblings, or domestic partners may also qualify. The interplay between wrongful death statutes and product liability discovery rules creates filing deadline complexities that can extinguish viable claims if not handled promptly.
Dupixent Lawsuit Lawsuit
Dupixent (dupilumab) is a monoclonal antibody biologic drug developed by Regeneron Pharmaceuticals and marketed jointly with Sanofi-Aventis and its subsidiary Genzyme Corporation. The FDA first approved Dupixent in March 2017 for adults with moderate-to-severe atopic dermatitis (eczema) who had not responded adequately to topical treatments. Subsequent FDA approvals expanded its use to moderate-to-severe asthma in October 2018, chronic rhinosinusitis with nasal polyps (CRSwNP) in June 2019, eosinophilic esophagitis (EoE) in May 2022, prurigo nodularis in September 2022, and chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype in September 2024. With more than 37 million prescriptions dispensed globally, Dupixent became one of the best-selling biologic drugs in the world, generating over $13 billion in annual revenue for its manufacturers. The drug works by inhibiting interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling — two cytokines that drive type 2 inflammation. While this mechanism was considered targeted and relatively safe, post-market surveillance and independent research have identified a concerning association between Dupixent use and cutaneous T-cell lymphoma (CTCL). CTCL is a rare cancer in which T-cells become malignant and attack the skin, often presenting initially as rashes or patches that can be mistaken for eczema. The critical concern is that symptoms of CTCL closely mimic the very conditions Dupixent is prescribed to treat, potentially masking the cancer and delaying diagnosis. A peer-reviewed study analyzing 19,612 patients found that Dupixent users faced a 4.5 times higher risk of developing CTCL compared to patients not using the drug. The FDA placed Dupixent on its drug safety watchlist in March 2025 and escalated to a formal investigation in September 2025 after receiving over 300 adverse event reports related to lymphoma and blood cancers. As of February 2026, individual lawsuits are being filed against Regeneron Pharmaceuticals, Sanofi-Aventis, and Genzyme Corporation. Plaintiffs allege that the manufacturers knew or should have known about the cancer risk and failed to adequately warn patients and prescribing physicians. Specific allegations include failure to warn, defective design of the drug's labeling, negligence in post-market surveillance, and fraudulent concealment of safety data. A wrongful death suit was filed in Tennessee in October 2025 on behalf of Chandra Richardson. Additional cases have been filed in Florida (January 2026) and Illinois (December 2025). Legal experts anticipate that the Judicial Panel on Multidistrict Litigation will consolidate federal cases into an MDL within the next 12 months.
View full case overview